Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis

Journal of Clinical Pharmacology

Volumn 43, Issue 1, 2003, Pages 43-51

  Wolf, Daniel L ^a   Rodríguez, Carlos A ^a,c   Mucci, Massimiliano ^b   Ingrosso, Antonella ^b   Duncan, Barbara A ^a   Nickens, Dana J ^a  

^a PFIZER INC   (United States)

^b Antiviral Clinical Development   (Italy)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; PROBENECID;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DOSE RESPONSE; DRUG MONITORING; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFUSION; KIDNEY FUNCTION; MALE; NEPHROTOXICITY; RANDOMIZED CONTROLLED TRIAL; RETINITIS; VIRUS LOAD;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS RETINITIS; CYTOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PROBENECID;

EID: 0037215294     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270002239705     Document Type: Article

References (22)

1. Gallant JE, Moore RD, Richman DD, Kenuly J, Chaisson RE: Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992;166:1223-1227.
2. Hoover DR, Saah AJ, Bacellar H, Phair J, Detels R, Anderson R, et al: Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. N EngI J Med 1993;329:1922-1926.
3. Au Eong KG, Beatty S, Charles SJ: Cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Postgrad Med J 1999;75:585-590.
4. Snoeck R, Sakuma T, DeClercq E, Rosenberg I, Holy A: (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 1988;32:1839-1844.
5. Neyts J, Sobis H, Snoeck R, Vandeputte M, De Clercq E: Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice. Eur J Clin Microbiol Infect Dis 1993;12:269-279.
6. Polis MA, Spooner KM, Baird BF, Manischewitz JF, Jaffe HS, Fisher PE, et al: Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother 1995; 39:882-886.
7. Van Cutsem E, Snoeck R, Van Ranst M, Fiten P, Opdenakker G, Geboes K, et al: Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J Med Virol 1995;45:230-235.
8. Plosker GL, Noble S: Cidofovir: A review of its use in cytomegalovirus retinitis in patients with AIDS. Drugs 1999;58:325-345.
9. Cihlar T, Votruba I, Horska K, Liboska R, Rosenberg I, Holy A: Metabolism of 1-(S)-(3-hydroxy-2-phosphonomethoxypropyl)-cytosine (HPMPC) in human embryonic lung cells. Collect Czech Chem Commun 1992;57:661-672.
10. Ho H-T, Woods KL, Bronson JJ, De Boeck H, Martin JC, Hitchcock MJM: Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol Pharmacol 1992;41:197-202.
11. Crumpacker CS: Ganciclovir. N Engl J Med 1996;335:721-729.
12. Wagstaff AJ, Bryson HM: Foscarnet: A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994;48:199-226.
13. Lee TA, Sullivan SD, Veenstra DL, Ramsey SD, Steger PJK, Malinverni R, et al: Economic evaluation of systemic treatments for cytomegalovirus retinitis in patients with AIDS. Pharmacoeconomics 2001;19:535-550.
14. Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, et al: (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): Results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995;171:788-796.
15. Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, et al: Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1997;126:257-263.
16. Lalezari JP, Holland GN, Kramer F, McKinley GF, Kemper CA, Ives DV, et al: Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Defic Syndrom Hum Retrovirol 1998;17:339-344.
17. Lacy SA, Hitchcock MJM, Lee WA, Tellier P, Cundy KC: Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol Sci 1998;44:97-106.
18. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
19. Eisenberg EJ, Cundy KC: HPLC determination of cytosine containing compounds by precolumn fluorescence derivatization with phenacyl bromide: Application to antiviral nucleosides and nucleotides. J Chromatogr 1996;679:119-127.
20. Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, et al: Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1995;39:1247-1252.
21. Brody SR, Humphreys MH, Gambertoglio JG, Schoenfeld P, Cundy KC, Aweeka FT: Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. Clin Pharmacol Ther 1999;65:21-28.
22. Cundy KC: Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 1999;36:127-143.